Pages that link to "Q34502250"

The following pages link to A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies (Q34502250):

Displaying 25 items.

• Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems (Q36744366) ‎ (← links)
• A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models (Q36835278) ‎ (← links)
• Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing (Q37030102) ‎ (← links)
• Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility (Q37211503) ‎ (← links)
• Effects of [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. (Q38833155) ‎ (← links)
• Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats (Q38915717) ‎ (← links)
• Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale (Q38969500) ‎ (← links)
• Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors (Q39015847) ‎ (← links)
• Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction. (Q39296074) ‎ (← links)
• In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. (Q41380155) ‎ (← links)
• Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands (Q41493064) ‎ (← links)
• In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403. (Q45998228) ‎ (← links)
• Occupancy of Nociceptin/Orphanin FQ Peptide Receptors by the Antagonist LY2940094 in Rats and Healthy Human Subjects (Q46526074) ‎ (← links)
• Advances in Pharmacotherapy Development: Human Clinical Studies (Q47182010) ‎ (← links)
• Panicolytic-like effects caused by substantia nigra pars reticulata pretreatment with low doses of endomorphin-1 and high doses of CTOP or the NOP receptors antagonist JTC-801 in male Rattus norvegicus (Q47300004) ‎ (← links)
• Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence (Q47409005) ‎ (← links)
• A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia. (Q47549684) ‎ (← links)
• Real-Time Functional Magnetic Resonance Imaging Amygdala Neurofeedback Changes Positive Information Processing in Major Depressive Disorder (Q47896005) ‎ (← links)
• Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness (Q48056790) ‎ (← links)
• Nociceptin Receptor as a Target to Treat Alcohol Use Disorder: Challenges in Advancing Medications Development. (Q51438275) ‎ (← links)
• Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic (Q58545262) ‎ (← links)
• Erratum: A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies (Q60054476) ‎ (← links)
• Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches (Q89326880) ‎ (← links)
• Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress (Q89871011) ‎ (← links)
• The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression (Q90708165) ‎ (← links)